Investigation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin levels in multiple sclerosis patients

Basit Öğe Kaydı
dc.contributor.authorKurban, Sevil
dc.contributor.authorAkpınar, Zehra
dc.contributor.authorMehmetoğlu, İdris
dc.date.accessioned2020-03-26T18:15:00Z
dc.date.available2020-03-26T18:15:00Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: The aim of this study was to investigate the osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) levels and their correlation with bone mineral density (BMD) and levels of other bone turnover parameters such as serum osteocalcin, parathyroid hormone (PTH), calcium, bone alkaline phosphatase (bALP) and urinary deoxypyridinoline (DPD) in patients with multiple sclerosis (MS). Methods: Forty six MS patients (30F, 16M, 33.48 +/- 9.57 years old) and 24 healthy controls (14F, 10M, 33.04 +/- 7.97 years old) were included in the study. Serum OPG, RANKL, bALP, osteocalcin, PTH, calcium, urinary DPD levels of all subjects, and BMD of 29 patients and all control subjects were measured. Osteoprotegerin and RANKL levels, bALP, osteocalcin and PTH levels, and urinary DPD levels were measured by ELISA method, chemiluminescent method, and HPLC technique. The BMD was measured by dual-X-ray absorptiometry. Results: Serum OPG (p<0.01), RANKL (p<0.01), bALP (p<0.05), PTH (p<0.01) and calcium (p<0.05) levels were significantly higher in MS patients than in controls. There was no significant difference between serum osteocalcin, urinary DPD levels and BMD measures of the groups. Conclusion: Increased RANKL levels associated with osteoclastogenesis suggests a tendency towards osteoporosis in MS patients. However, no significant change in BMD levels of the subjects shows that the effect of RANKL is compensated by increased OPG levels. OPG and RANKL levels are involved in the pathogenesis and regulation of bone turnover and thus, circulating levels of them may be useful markers to assess bone turnover and to develop new approaches in MS.en_US
dc.description.sponsorshipUniversity of SelcukSelcuk University; Department (BAP), Konya-Turkeyen_US
dc.description.sponsorshipThis research was supported by Grant 08401097 from University of Selcuk, Scientific Research Projects Department (BAP), Konya-Turkey. The study was presented as an oral presentation at XXI National Biochemistry Congress, November 28-31, 2009, Istanbul, Turkey.en_US
dc.identifier.endpage142en_US
dc.identifier.issn0250-4685en_US
dc.identifier.issn1303-829Xen_US
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage136en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26581
dc.identifier.volume36en_US
dc.identifier.wosWOS:000300974200007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWALTER DE GRUYTER GMBHen_US
dc.relation.ispartofTURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectBone mineral densityen_US
dc.subjectMultiple sclerosisen_US
dc.subjectOsteoporosisen_US
dc.subjectOsteoprotegerinen_US
dc.subjectReceptor activator of NF-kappaB liganden_US
dc.titleInvestigation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin levels in multiple sclerosis patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu